Compare Duke Energy Corp (DUK) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Merck & Co., Inc. — how do they compare? Duke Energy Corp trades at $116.65 (market cap $91.10B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 3.9× Duke Energy Corp's market cap, and Duke Energy Corp pays the higher dividend (3.71%). Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and Merck & Co., Inc. for 98 Days on average.
| DUK | MRK | |
|---|---|---|
Market Cap | $91.10B | $351.28B |
Volume | 4,199,050 | 7,969,665 |
Sector | Utilities | Health |
52-Week High | $133.46 | $156.43 |
52-Week Low | $113.23 | $82.49 |
Typical Hold Time | 74 Days | 98 Days |
Enterprise Value | $183.61B | $398.04B |
Dividend Yield | 3.71% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $116.84, up 1.16% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 15.78% net margin, and stable dividend payments. Revenue growth accelerated from $28.8B in 2022 to $32.24B in 2025, with positive cash flow trends emerging in 2026 forecasts.
DUK offers a balanced investment case with 40.6% analyst buy ratings and $134.44 consensus target, representing 15% upside. Key risks include rising Treasury yields pressuring utility stocks and elevated debt levels at 46.17% of assets. The data center expansion opportunity provides growth catalysts amid regulatory stability.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
